You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康希諾生物(6185.HK)仍未止跌 即便澄清稱百萬人測試中未見血栓報吿
格隆匯 04-15 10:10
格隆匯4月15日丨昨天一度大跌超18%的康希諾生物(6185.HK)今日仍未止跌,現跌近5%,報274.8港元,總市值680億港元。隨更多新冠疫苗面世,先後有疫苗爆出發現未知原故副作用,強生疫苗、阿斯利康疫苗先後因為疑似引發血栓風險,被多國停用,康希諾生物新冠疫苗使用與強生疫苗、阿斯利康牛津疫苗同類的“腺病毒載體疫苗”技術,引發市場拋售康希諾生物。康希諾昨日午間發表自願公吿稱,公司所用的重組新型冠狀病毒疫苗,載體為5型腺病毒,為一種常見的感染人的腺病毒,與阿斯利康新冠疫苗所使用的黑猩猩腺病毒載體和強生新冠疫苗所使用的26型腺病毒載體不同。康希諾生物表示,截至公吿日,接種康希諾疫苗的約百萬人中未收到與血栓相關的嚴重不良事件報吿。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account